ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers.
ViaNautis has raised $27.1M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2026.
ViaNautis's investors include Eli Lilly, 4BIO Capital, Cystic Fibrosis Foundation, Abcam, SCI Ventures.
ViaNautis is headquartered in Cambridge, United Kingdom.
ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers.
ViaNautis is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ViaNautis — Funding & Investors." VCBacked, September 9, 2026, https://www.vcbacked.co/company/vianautis. Accessed October 28, 2026.
VCBacked. (2026). ViaNautis — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/vianautis
{{cite web |title=ViaNautis — Funding & Investors |url=https://www.vcbacked.co/company/vianautis |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated